Document is current
Any future updates will be listed below
-
Authors
Davids, Matthew S. https://orcid.org/0000-0003-4529-2003
Stilgenbauer, Stephan https://orcid.org/0000-0002-6830-9296
Tam, Constantine S. https://orcid.org/0000-0002-9759-5017
- License Information
-
More Information
Article History
Received: 5 September 2024
Revised: 25 November 2025
Accepted: 12 December 2025
First Online: 8 January 2026
Competing interests
: MSD: Research funding from Ascentage Pharma, MEI Pharma, and Novartis; honoraria from AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeOne Medicines Ltd, BMS, Eli Lilly, Genentech, Genmab, Janssen, Merck, Nuvalent, Secura Bio, Takeda Pharmaceuticals, and TG Therapeutics. SS: Honoraria from AbbVie, Acerta Pharma, Amgen, AstraZeneca, BeOne Medicines Ltd, BMS, Celgene, Eli Lilly, F. Hoffmann-La Roche, Gilead Sciences, GSK, Janssen, Novartis, and Sunesis Pharmaceuticals. CST: Research funding from AbbVie, BeOne Medicines Ltd, and Janssen; honoraria from AbbVie, AstraZeneca, BeOne Medicines Ltd, Janssen, and Merck.
